The laboratory pr dé feels dé Saturday August 30 & ucirc, t r dé results tr & egrave, s expected of this clinical trial call dé LCZ696 during the congress & egrave, s of the League dé t & eacute; European dé uropean Heart r dé united this weekend & agrave ; Barcelona, Spain.
These data dé es have dé t & eacute; published dé are simultaneous dé ment in the journal m dé of association am dé -American New England Journal of Medicine.
R dé reduction in mortality dé and hospitalizations.
Men dé e AUPR & egrave, s of 8442 patients in 47 countries followed for 27 months, this dé study, the largest ever r dé alis dé e, & was agrave ; dé evaluate the harmlessness dé and effectiveness dé of this treatment in patients with heart failure by comparing with those flavou dé s with enalapril, the current treatment of choice.
At the end of this p dé period of observation, 21.8% of participants related dé s with LCZ696 died of heart failure and 26.5 % in those related dé s with enalapril, which represents dé feel 20 % less.
The laboratory has underlined dé in a statement dé the magnitude of the benefits of this treatment dé was & quot; Statistically and clinically tr & egrave ; important s & quot;.
Besides r dé reduction in mortality dé Cardiovascular this dé study was dé also dé shown dé that m dé dicament r dé duisait 21% the number of hospitalizations for heart failure.
& quot; think when I m dé doctors will see these r dé results, they will find compelling and we will see & agrave ; a complete change in the treatment of heart failure & quot ;, has estimated dé Dr. Milton Packer, a professor of clinical sciences & agrave ; Universit é ; South Texas & agrave ; Dallas, one of the main authors of the dé study.
Despite dé existing treatments, the mortality rate dé heart failure remains dé dé lev ;, with up & agrave ; 50% of patients dé c dé ing within five years after & egrave ; ‘s diagnosis, has no dé laboratory.
Heart failure, which emp & ecirc ; che the heart to pump enough blood to the organs, cause your icirc ; does shortness of breath, fatigue and r dé intention of fluid in the lower members dé laughing.
According to several analysts, the new treatment may become a & quot; Blockbuster & quot ;, a m dé dicament whose sales dé spend a billion dollars a year.
Novartis pr dé sees dé ask authorization applications isation dé AUPR & egrave, s agency am dé -American of m dé drugs, the Food and Drug Administration by the end of 2014 and AUPR & egrave, s his dé equivalent of the Union Europ dé enne dé goal in 2015.
Novartis had announced dé last March it was terminating & agrave ; this trial more t & OCIRC ; cy pr dé seen as treatment dé was significantly sup dé laughing & agrave ; enalapril, m dé dicament most used dé currently against heart failure, hypertension art dé -sectoral and dysfunction of the left ventricle of the heart.
But this new treatment is likely & ecirc ; very expensive, according to analyst Tim Anderson, the firm Sanford C.
Bernstein, cit dé The New York Times.
According to him, this treatment could ucirc & Co ; ter seven dollars per day in the United States or 2,500 dollars per year while the g & versions eacute n dé cal other treatments against heart failure can come back & agrave ; $ 4 a day.
Among the most en é side effects of LCZ696 quently, these researchers relev dé more hypotension but less problems & egrave ; my r dé nal.
Source: Communiqu dé Press Novartis August 28 & ucirc ; 2014 t..